Navigation Links
NYU scientists identify critical protein complex in formation of cell cilia
Date:8/19/2008

ver design drugs that will restore the formation and function of cilia even in the presence of CEP290 mutations, then that would be one way to cure the defects that lead to ciliary diseases."

Research so far has been using in vitro human cell lines. However, team members from the University of Michigan and National Eye Institute have developed a mouse model with a CEP290 mutation implicated in retinal degeneration, and the NYU group is planning a study of human CEP290 mutations to see if they can correlate genotypes to their expression in specific ciliary diseases.


'/>"/>

Contact: Jennifer Berman
Jennifer.Berman@nyumc.org
212-404-3555
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Johns Hopkins scientists discover what drives the development of a fatal form of malaria
2. Smithsonian scientists discover new bird species
3. Scientists discover major genetic cause of colorectal cancer
4. Scientists overcome nanotech hurdle
5. Strange molecule in the sky cleans acid rain, scientists discover
6. Scientists team up in Houston to tackle global challenges
7. Scientists find elephant memories may hold key to survival
8. Scientists to assess Beijing Olympics air pollution control efforts
9. Scripps scientists will assess Beijing Olympics air pollution control efforts
10. Midge-hunting scientists tackle spread of devastating bluetongue virus
11. Scientists a step closer to producing fuel from bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...am (EEG) is widely used by physicians and scientis...gical disorders. However, it has remained largely ... exact view of what is happening inside the brain....ical Cybernetics in Tbingen, Germany, have now fou...ithin the brain to that measured with EEG. These f...
(Date:12/4/2009)...al model of heart cells, University of Iowa invest...zyme, calmodulin kinase II (CaM kinase), disrupts ...study, which also involved Columbia University, wa...putational Biology . , "Recently, researchers h...II as a critical regulator of the heart,s response...
(Date:12/3/2009)..., Dec. 3 BIO-key Interna...in wireless public safety and finger-based biometr...rity of its shareholders at a Special Shareholder ...y,s Law Enforcement Division to Interact911 Mobile... in favor and 1.2% were opposed. ,, (Logo: htt...
Breaking Biology News(10 mins):How to read brain activity? 2U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Union of American Physicians and Dentists 3A Court Appointee El Sabaawi Practicing Medicine Without a License 3F 52846 1Union of American Physicians and Dentists 3A Court Appointee El Sabaawi Practicing Medicine Without a License 3F 52846 2SEQUENOM Announces Launch of MassARRAY Compact 96 System 13217 1SEQUENOM Announces Launch of MassARRAY Compact 96 System 13217 2SEQUENOM Announces Launch of MassARRAY Compact 96 System 13217 3SEQUENOM Announces Launch of MassARRAY Compact 96 System 13217 4Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 1Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 2Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 3Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 4Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 5Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 6
... WHITE PLAINS, NY Babies born preterm were more t... full-term infants, according to a new analysis of...e this week in the Springer journal Maternal and C... before 37 completed weeks gestation, is a growing... Dimes. More than a half million babies are born t...
...own as neurons process information by joining into...her across junctions called synapses. But neurons ...Josh Huang, Ph.D., in a lot of cases, they connect... Dr. Huang, a professor at Cold Spring Harbor Lab...olecules guiding this highly specific neuronal tar...
...iologists from Austria and Singapore developed a t... between biology and art. In an article recently p...fasebj.org ) and scheduled for the August 2008 pri... able to coator paintviruses with proteins. This b... efficiency of some forms of gene therapy, help tr...
Other Biology News:Analysis of millions of US births shows association between birth defects and preterm birth 2Scientists discover a molecular scaffold that guides connections between brain cells 2Scientists discover a molecular scaffold that guides connections between brain cells 3Scientists 'paint' viruses to track their fate in the body 2
(Date:12/2/2009)..., Dec. 2 Peregrine Pharm...ompletion of patient enrollment in a dose confirma...ts with relapsed glioblastoma multiforme (GBM), th...geted monoclonal antibody linked to a radioisotope...GBM. Cotara specifically targets cells at the cen...
(Date:12/2/2009)...e Netherlands, December 2 Pepscan ...mpany focusing on protein mimicking,technology for...nced that it,has appointed Wim E.M. Mol, Ph.D. as ...ll be responsible for all of Pepscans corporate fu...irection of the company. He brings to,Pepscan more...
(Date:12/2/2009)...Dec. 2 S*BIO Pte Ltd today announc...itor, SB1518, at The American Society of Hematolog...s. ,, Data will be presented on the clinical re...1518 detailing its safety, tolerability and pharma...levels ranging from 100 to 600 mg. These doses wer...
(Date:12/2/2009)... 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ...al biopharmaceutical company focused on endocrine .... Food and Drug Administration (FDA) has granted F...athway inhibitor compound, perifosine (KRX-0401), ...myeloma. Keryx Biopharmaceuticals, Inc. ("Keryx") ...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3
...,Bulletin Board: AIMM) today reported a net loss o...ed, for the three months ended September 30, 2008,...per share basic and,diluted, for the three months ...d September 30, 2008, the net loss was $216,000, o... net loss of $62,000, or break even per,share basi...
...aq: OSTE ), a leader in the emerging field of bio... today that its next generation grafting,material ...M) Bone Graft., Robert M. Wynalek, Osteotech,s Pr...line of next generation bone regeneration products...a high performing, cost,effective bone graft mater...
...HD) today announced that its executives will be sp...invited investors to participate via webcast., ...oenix, AZ Friday, November 14, 2008 at 8.00 a...Conference, New York, NY Tuesday, December 2,...s, To access the live webcasts for these events, ...
Other Biology Technology:AutoImmune Inc. Reports 2008 Third Quarter Financial Results 2AutoImmune Inc. Reports 2008 Third Quarter Financial Results 3Osteotech's Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio 2Osteotech's Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio 3Cepheid to Webcast Upcoming Financial Presentations 2
Annexin V Binding Buffer from BD Biosciences Pharmingen
Mouse Anti-Human p53, wild & mutant, aa 19-26 Monoclonal Antibody, Unconjugated, Clone DO-7 from CHEMICON
Anti-Feline Rhinotracheitis Virus Monoclonal Antibody, Unconjugated from ViroStat Inc.
Rabbit Anti-Survivin DEx3 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: